Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer

International Journal of Cancer

Volumn 95, Issue 4, 2001, Pages 255-259

  Egawa, Chiyomi ^a   Miyoshi, Yasuo ^a   Takamura, Yuuki ^a   Taguchi, Tetsuya ^a   Tamaki, Yasuhiro ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

BRCA1; BRCA2; Breast cancer; Docetaxel; Prediction

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; GLYCOPROTEIN P; MESSENGER RNA; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN MIBI; PROTEIN P53; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL MARKERS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; PACLITAXEL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; RNA, NEOPLASM; TAXOIDS; TRANSCRIPTION FACTORS;

EID: 0035919888     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20010720)95:4<255::AID-IJC1043>3.0.CO;2-O     Document Type: Article

References (31)

1. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
2. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13
3. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer
4. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13
5. Insights into the functions BRCA1 and BRCA2
6. Association of BRCA1 with Rad51 in mitotic and meiotic cells
7. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells
8. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells
9. Acceleration of chromosomal instability by loss of BRCA1 expression and p53 abnormality in sporadic breast cancers
10. Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer
11. A somatic truncating mutation in BRCA2 in a sporadic breast tumor
12. BRCA2 mutations in primary breast and ovarian cancers
13. Mutation analysis in the BRCA2 gene in primary breast cancers
14. Decreased expression of BRCA 1 accelerates growth and is often present during sporadic breast cancer progression
15. Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers
16. Overexpression of BRCA2 gene in sporadic breast tumours
17. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells
18. Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers
19. Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer
20. Studies with RP56976 (Taxotere): A semisynthetic analogue of Taxol
21. Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers
22. P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer
23. Prediction of response to primary chemotherapy for operable breast cancer
24. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients
25. Interaction of docetaxel ("Taxotere") with human P-glycoprotein
26. Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells
27. Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene
28. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes
29. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations
30. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer
31. Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: Partial cross-resistance between paclitaxel and docetaxel